Yuanshang Bio to List on OTC Market in Early June, Aims for One Licensing Deal Per Year Within Three Years
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
Yuanshang Bio, a new drug company, announced its upcoming listing on the over-the-counter market in early June and aims to secure at least one licensing agreement annually within the next three years. It focuses on developing bispecific antibody new drugs for ophthalmology and oncology.